Neutral impactResults
Torrent Pharmaceuticals Q2 FY27 Results: Key Highlights
Kalkine India 1d ago·23 Oct 2026, 11:20 am
Torrent Pharmaceuticals has released its financial results for the second quarter of fiscal year 2027. The company reported a mixed performance, with its consolidated net profit declining by 13% year-on-year to Rs 321 crore. Despite this dip, the company’s revenue from operations grew by 7% to Rs 1,846 crore, driven by strong demand for its key therapeutic products in the US and India markets.
The decline in profit was primarily due to higher raw material costs and increased marketing expenses. However, the growth in revenue is a positive sign for investors, indicating that the company's core business is expanding. The company's focus on niche therapeutic segments and its strong pipeline of new products are expected to drive future growth.
Investors should watch for the company's guidance on future growth, particularly in the US market. The company's ability to manage costs and maintain its market share will be crucial for its future performance. The upcoming earnings call will provide more insights into the company's strategy and outlook.
Excerpt from Kalkine India
Source: Krish Capital Pty Ltd Torrent Pharmaceuticals (NSE:TORNTPHARM) disclosed on 23 October 2026 that its board approved audited standalone financial results and unaudited consolidated financial results for the quarter and half year ended 30 September 2026, with the audit conducted by B S R & Co. LLP. The results…Read the original at Kalkine India
Affected stocks
Neutral1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Torrent Pharmaceuticals (TORNTPHARM).
- Category: Results.
Why it matters
A routine update for Torrent Pharmaceuticals. Use the price and stock snapshot to gauge how the market is responding.
